CLINICAL RESEARCH: CAROTID AND PERIPHERAL ATHEROSCLEROSIS
Myeloperoxidase Predicts Progression of Carotid Stenosis in States of Low High-Density Lipoprotein Cholesterol
Markus Exner, MD*,
Erich Minar, MD ,
Wolfgang Mlekusch, MD,
Schila Sabeti, MD,
Jasmin Amighi, MD,
Wolfgang Lalouschek, MD ,
Gerald Maurer, MD ,
Christian Bieglmayer, PhD*,
Heidi Kieweg*,
Oswald Wagner, MD* and
Martin Schillinger, MD,*
* Departments of Medical and Chemical Laboratory Diagnostics, Medical University Vienna, Vienna, Austria
Department of Angiology, Medical University Vienna, Vienna, Austria
Department of Neurology, Medical University Vienna, Vienna, Austria
Department of Cardiology, Medical University Vienna, Vienna, Austria
Manuscript received November 7, 2005;
revised manuscript received January 11, 2006,
accepted January 16, 2006.
* Reprint requests and correspondence: Dr. Martin Schillinger, Division of Angiology, Department of Internal Medicine II, Medical University Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria. (Email: martin.schillinger{at}meduniwien.ac.at).
OBJECTIVES: We investigated the effect of myeloperoxidase (MPO) on progression of carotid stenosis in states of high and low high-density lipoprotein-cholesterol (HDL-C) and low-density lipoprotein-cholesterol (LDL-C) levels.
BACKGROUND: Myeloperoxidase is pivotally involved in the pathogenesis of atherosclerosis. In vitro data suggest that MPO exerts deleterious effects via oxidative modulation of lipoproteins.
METHODS: We prospectively studied 1,019 of 1,268 consecutive patients who were asymptomatic with respect to carotid artery disease. Patients underwent serial carotid ultrasound investigations at baseline and after a follow-up interval of median 7.5 months (range 6 to 9 months), categorizing carotid arteries as 0% to 29%, 30% to 49%, 50% to 69%, 70% to 89%, or 90% to 99% stenosed or occluded. The MPO, HDL-C, and LDL-C levels were measured at baseline, grouped by medians, and correlated with progression of carotid atherosclerosis.
RESULTS: Progression of carotid atherosclerosis was found in 100 of 1,019 patients (9.8%). Myeloperoxidase (p = 0.014) but not HDL-C (p = 0.95) or LDL-C (p = 0.30) were associated with progressive disease. However, MPO  310 ng/ml was significantly associated with progressive disease (adjusted odds ratio [OR] 2.57, 95% confidence interval [CI] 1.39 to 4.75) only in patients with HDL-C levels <49 mg/dl. Otherwise, in patients with higher HDL-C levels (49 mg/dl), MPO 310 ng/ml did not predict disease progression (adjusted OR 1.42, 95% CI 0.72 to 2.78). No interaction of MPO with LDL-C was observed.
CONCLUSIONS: Myeloperoxidase was associated with progression of carotid atherosclerosis in patients with HDL cholesterol levels below 49 mg/dl.
|
Abbreviations and Acronyms
| | CI = confidence interval | | CRP = C-reactive protein | | HDL-C = high-density lipoprotein cholesterol | | hs-CRP = high-sensitivity C-reactive protein | | ICA = internal carotid artery | | IQR = interquartile range | | LDL-C = low-density lipoprotein cholesterol | | MPO = myeloperoxidase | | OR = odds ratio | | SAA = serum amyloid A |
|
This article has been cited by other articles:
|
|
|
|
 
P Gururajan, P Gurumurthy, P Nayar, S Babu, A Sarasabharati, D Victor, and K M Cherian
Serum myeloperoxidase: a novel biomarker for evaluation of patients with acute coronary syndrome
Heart Asia,
October 15, 2009;
2009(10):
1 - 6.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. D. Wong, H. Gransar, J. Narula, L. Shaw, J. H. Moon, R. Miranda-Peats, A. Rozanski, S. W. Hayes, L. E.J. Thomson, J. D. Friedman, et al.
Myeloperoxidase, Subclinical Atherosclerosis, and Cardiovascular Disease Events
J. Am. Coll. Cardiol. Img.,
September 1, 2009;
2(9):
1093 - 1099.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. K. Schindhelm, L. P. van der Zwan, T. Teerlink, and P. G. Scheffer
Myeloperoxidase: A Useful Biomarker for Cardiovascular Disease Risk Stratification?
Clin. Chem.,
August 1, 2009;
55(8):
1462 - 1470.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. K. Rudolph, V. Rudolph, and S. Baldus
Contribution of Myeloperoxidase to Smoking-dependent Vascular Inflammation
Proceedings of the ATS,
December 1, 2008;
5(8):
820 - 823.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Reiter, I. Effenberger, S. Sabeti, W. Mlekusch, O. Schlager, P. Dick, S. Puchner, J. Amighi, R. A. Bucek, E. Minar, et al.
Increasing Carotid Plaque Echolucency is Predictive of Cardiovascular Events in High-Risk Patients
Radiology,
September 1, 2008;
248(3):
1050 - 1055.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Leclercq, X. Houard, M. Philippe, V. Ollivier, U. Sebbag, O. Meilhac, and J.-B. Michel
Involvement of intraplaque hemorrhage in atherothrombosis evolution via neutrophil protease enrichment
J. Leukoc. Biol.,
December 1, 2007;
82(6):
1420 - 1429.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Sabeti, O. Schlager, M. Exner, W. Mlekusch, J. Amighi, P. Dick, G. Maurer, K. Huber, R. Koppensteiner, O. Wagner, et al.
Progression of Carotid Stenosis Detected by Duplex Ultrasonography Predicts Adverse Outcomes in Cardiovascular High-Risk Patients
Stroke,
November 1, 2007;
38(11):
2887 - 2894.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Schlager, M. Exner, W. Mlekusch, S. Sabeti, J. Amighi, P. Dick, O. Wagner, R. Koppensteiner, E. Minar, and M. Schillinger
C-Reactive Protein Predicts Future Cardiovascular Events in Patients With Carotid Stenosis
Stroke,
April 1, 2007;
38(4):
1263 - 1268.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. N. DeMaria, O. Ben-Yehuda, G. K. Feld, G. S. Ginsburg, B. H. Greenberg, W. Y.W. Lew, J. A.C. Lima, A. S. Maisel, J. Narula, D. J. Sahn, et al.
Highlights of the Year in JACC 2006
J. Am. Coll. Cardiol.,
January 30, 2007;
49(4):
509 - 527.
[Full Text]
[PDF]
|
|
|
|
